Choi Eun Young, Park Dong-Ah, Kim Hyun Jung, Park Jinkyeong
Department of Pulmonary and Critical Care Medicine, Yeungnam University College of Medicine, Daegu, Republic of Korea.
Office of Health Technology Evaluation, National Evidence-Based Healthcare Collaborating Agency, Seoul, Republic of Korea.
Ann Intensive Care. 2015 Dec;5(1):31. doi: 10.1186/s13613-015-0073-9. Epub 2015 Oct 7.
We performed a meta-analysis of randomized controlled trials (RCTs) to determine if daily bathing with chlorhexidine decreased hospital-acquired BSIs in critically ill patients.
We searched the MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials databases to identify randomized controlled trials that compared daily bathing with chlorhexidine and a control in critically ill patients.
This meta-analysis included five RCTs. The overall incidence of measured hospital-acquired BSIs was significantly lower in the chlorhexidine group compared to the controls 0.69 (95 % CI 0.55-0.85; P < 0.001; I (2) = 57.7 %). Gram-positive-induced (RR = 0.49, 95 % CI 0.41-0.58; P = 0.000; I (2) = 0.0 %) bacteremias were significantly less common in the chlorhexidine group. The incidence of MRSA bacteremias (RR 0.63; 95 % CI 0.44-0.91; P = 0.006; I (2) = 30.3 %) was significantly lower among patients who received mupirocin in addition to chlorhexidine bathing than among those who did not routinely receive mupirocin.
Daily bathing with chlorhexidine may be effective to reduce the incidence of hospital-acquired BSIs. However, chlorhexidine bathing alone may be of limited utility in reduction of MRSA bacteremia; intranasal mupirocin may also be required. This meta-analysis has several limitations. Future large-scale international multicenter studies are needed.
我们进行了一项随机对照试验(RCT)的荟萃分析,以确定在重症患者中每日使用氯己定沐浴是否能降低医院获得性血流感染(BSIs)。
我们检索了MEDLINE、EMBASE和Cochrane对照试验中心注册库数据库,以识别比较在重症患者中每日使用氯己定沐浴与对照的随机对照试验。
该荟萃分析纳入了五项随机对照试验。与对照组相比,氯己定组中测量的医院获得性血流感染的总体发生率显著更低,为0.69(95%置信区间0.55 - 0.85;P < 0.001;I² = 57.7%)。革兰氏阳性菌引起的菌血症(相对危险度 = 0.49,95%置信区间0.41 - 0.58;P = 0.000;I² = 0.0%)在氯己定组中明显更少见。除氯己定沐浴外还接受莫匹罗星治疗的患者中,耐甲氧西林金黄色葡萄球菌(MRSA)菌血症的发生率(相对危险度0.63;95%置信区间0.44 - 0.91;P = 0.006;I² = 30.3%)显著低于未常规接受莫匹罗星治疗的患者。
每日使用氯己定沐浴可能有效降低医院获得性血流感染的发生率。然而,单独使用氯己定沐浴在降低MRSA菌血症方面可能效用有限;可能还需要鼻内使用莫匹罗星。该荟萃分析有几个局限性。未来需要进行大规模的国际多中心研究。